Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
E: werner.lanthaler@evotec.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,580.00 | 6.70 | -0.08% |
CAC 40 | 7,734.40 | 130.04 | -1.65% |
DAX 40 | 23,629.58 | 369.59 | -1.54% |
Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
FTSE 100 | 8,717.97 | 21.29 | -0.24% |
HKSE | 23,530.36 | 70.90 | -0.30% |
NASDAQ | 18,737.21 | 188.53 | -1.00% |
Nikkei 225 | 37,329.22 | 168.75 | 0.45% |
NZX 50 Index | 12,547.69 | 48.81 | -0.39% |
S&P 500 | 5,802.82 | 39.19 | -0.67% |
S&P/ASX 200 | 8,351.40 | 9.50 | -0.11% |
SSE Composite Index | 3,360.93 | 12.56 | 0.38% |